Skip to main content
Clinical Trials/NL-OMON44113
NL-OMON44113
Completed
Not Applicable

Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies - SPRINTT

Medisch Universitair Ziekenhuis Maastricht0 sites100 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Physical frailty
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • \- Participants have to be willing to be randomised to either intervention group and to follow study protocol
  • \- Men and women
  • \- Aged 70 years and older
  • \- SPPB score ranging between 3 (included) and 9 (included)
  • \- Ability to complete 400\-m walk test within 15 minutes without sitting down, the help of another person or the use of a walker
  • \- Presence of low muscle mass according to results from a DXA scan and in agreement with the Foundation for the National Institutes of Health Sarcopenia Project (FNIH) reports.

Exclusion Criteria

  • \- Unable or unwilling to provide informed consent or accept randomisation in either study group
  • \- Plans to relocate out of the study area within the next 2 years or plans to be out of the study area for more than 6 consecutive weeks in the next year
  • \- Nursing\-home residence
  • \- Household member enrolled in the study
  • \- Current diagnosis of schizophrenia, other psychotic or bipolar disorder
  • \- Consumption of more than 14 alcoholic drinks per week
  • \- Difficulty communicating with the study personnel due to speech, language, or (non\-corrected) hearing problems
  • \- MMSE lower than 24/30
  • \- Severe arthritis (e.g., awaiting joint replacement) that would interfere with the ability to participate fully in either study arm
  • \- Cancer requiring treatment in the past 3 years, except for non\-melanoma skin cancers or cancers that have an excellent prognosis (e.g., early stage breast or prostate cancer)

Outcomes

Primary Outcomes

Not specified

Similar Trials